Michael Wang, MD¹, Nirav N. Shah, MD², Alvaro J. Alencar, MD³, James N. Gerson, MD⁴, Manish R. Patel, MD⁵, Bita Fakhri, MD, MPH⁶, Wojciech Jurczak, MD, PhD⁷, Xuan Ni Tan, MD^8*, Katharine L Lewis, MBBS⁸, Timothy S. Fenske, MD⁹, Catherine C. Coombs, MD¹⁰, Ian W. Flinn, MD, PhD¹¹, David John Lewis, MD^12*, Steven Le Gouill, MD, PhD¹³, M. Lia Palomba, MD¹⁴, Jennifer A. Woyach, MD¹⁵, John M. Pagel, MD PhD¹⁶, Nicole Lamanna, MD¹⁷, Jonathon B. Cohen, MD, MS¹⁸, Minal Barve, MD^19*, Paolo Ghia, MD, PhD²⁰, Toby A. Eyre^21*, Ming Yin^22*, Binoj Nair, PhD^22*, Donald Tsai, MD, PhD²², Nora C. Ku, MD^22*, Anthony Mato, MD^14* and Chan Yoon Cheah, MBBS⁸

¹Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
²Medical College of Wisconsin, Brookfield, WI
³Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
⁴Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁵Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, FL
⁶Division of Hematology and Oncology, University of California, San Francisco, CA
⁷Department of Hematology, Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland
⁸Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
⁹Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
¹⁰Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
¹¹Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
¹²Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom
¹³Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France
¹⁴Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹⁶Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
¹⁷Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
¹⁸Winship Cancer Institute, Emory University, Atlanta, GA
¹⁹Mary Crowley Cancer Research, Dallas, TX
²⁰Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, MI, Italy
²¹Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom
²²Loxo Oncology at Lilly, Stamford, CT

Maria Lia Palomba, MD¹, Leo I. Gordon, MD², Tanya Siddiqi, MD^3*, Jeremy S. Abramson, MD^4*, Manali Kamdar, MD^5*, Matthew A. Lunning, DO, FACP⁶, David G. Maloney, MD, PhD⁷, Charalambos Andreadis, MD, MSCE^8*, Jon E. Arnason, MD⁹, Nilanjan Ghosh, MD, PhD¹⁰, Amitkumar Mehta, MD¹¹, Scott R. Solomon, MD¹², Thalia Farazi, MD, PhD^13*, Jacob Garcia, MD^13*, Christine Dehner, BSc^13*, Ken Ogasawara, PhD, MPH^14*, Jie Gao, PhD^14* and Michael Wang, MD¹⁵

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
³City of Hope National Medical Center, Duarte, CA
⁴Massachusetts General Hospital Cancer Center, Boston, MA
⁵University of Colorado Cancer Center, Aurora, CO
⁶University of Nebraska Medical Center, Omaha, NE
⁷Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
⁹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
¹⁰Levine Cancer Institute, Atrium Health, Charlotte, NC
¹¹University of Alabama at Birmingham, Birmingham, AL
¹²Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA
¹³Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA
¹⁴Bristol-Myers Squibb Company, Princeton, NJ
¹⁵Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX

Zachary D. Epstein-Peterson, MD¹, Connie Lee Batlevi, MD, PhD², Philip Caron, MD, PhD¹, Ahmet Dogan, MD, PhD³, Pamela Drullinsky, MD^1*, John Gerecitano, MD, PhD⁴, Audrey Hamilton, MD^1*, Paul A. Hamlin, MD¹, Caleb Ho, MD³, Allison P. Jacob^5*, Leana Laraque, BA^2*, Matthew J Matasar, MD, MS¹, Alison J. Moskowitz, MD¹, Craig H. Moskowitz, MD⁶, Chelsea D Mullins, BS^5*, Colette Owens, MD¹, Gilles Salles⁷, Heiko Schöder, MD^8*, David J. Straus, MD¹, Anas Younes, MD⁹, Andrew D Zelenetz, MD, PhD¹ and Anita Kumar, MD¹

¹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴The Janssen Pharmaceutical Companies of Johnson & Johnson, West New York, NJ
⁵Adaptive Biotechnologies, Seattle, WA
⁶Department of Medicine, University of Miami Sylvester Sylvester Comprehensive Cancer Center, Miami, FL
⁷Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁹AstraZeneca, New York, NY

Mary B. Callanan, PhD^1*, Elizabeth Macintyre, PhD, MD², Marie-Helene Delfau-Larue, MD, PhD^3,4*, Catherine Thieblemont, MD, PhD⁵, Lucie Oberic, MD^6,7*, Emmanuel Gyan, MD, PhD⁸, Krimo Bouabdallah, MD^9*, Rémy Gressin, MD^10*, Gandhi Damaj, MD, PhD^11*, Olivier Casasnovas, MD^12*, Vincent Ribrag, MD¹³, Samuel Griolet^14*, Bénédicte Burlet^15*, Benjamin Tournier, Ph.D^16*, Sylviane Ragot, M.Sc^17*, Caroline Bodet-Milin^18*, Olivier Hermine^19,20 and Steven Le Gouill, MD, PhD²¹

¹University Hospital F. Mitterrand and Inserm UMR 1231, DIJON, France
²Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, Paris, France
³INSERMU955 équipe 9, Institut Mondor de Recherche Biomédicale, Créteil, France
⁴Department of Immunology, Hopital Henri Mondor, Creteil, France
⁵Department of Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France
⁶Department of Hematology, Institut Universitaire Cancerologie Toulouse-Oncopole, Toulouse, France
⁷Department of Hematology, Purpan University Hospital, Toulouse, France
⁸Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France
⁹Department of Hematology, University Hospital of Bordeaux, Pessac, France
¹⁰Department of clinical hematology., Centre Hospitalier et Universitaire de Grenoble-Alpes, Grenoble, France
¹¹Department of Hematology, Caen University Hospital, Caen, France
¹²Hematology Department, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
¹³Institut Gustave Roussy, Villejuif, France
¹⁴Centre Hospitalier Lyon Sud, Lymphoma Academic Research Organisation (LYSARC), Lyon, France
¹⁵Faculty of Medicine, University of Burgundy, INSERM 1231, Dijon University Hospital, Dijon, France
¹⁶Faculty of Medicine, University of Burgundy, INSERM1231, Dijon University Hospital, Dijon, France
¹⁷University of Burgundy, INSERM 1231, Dijon University Hospital, Dijon, France
¹⁸Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France
¹⁹Imagine Institute, INSERM U1163, University of Paris, Paris, France
²⁰Clinical Hematology, Necker University Hospital, Paris, France
²¹Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

Michael Wang, MD¹, Jacqueline C. Barrientos, MD², Richard R. Furman, MD³, Matthew Mei, MD⁴, Paul M. Barr, MD⁵, Michael Y. Choi, MD⁶, Sven de Vos, MD, PhD⁷, Avyakta Kallam, MD⁸, Krish Patel, MD⁹, Simon Rule, MD, PhD^10*, Kate Flanders, BS^10*, Katti A. Jessen, PhD¹⁰, Peter C. Riebling^11*, Patricia Graham, BHSA^12*, Lydia King, PhD^12*, Elizabeth M. Schmidt, BSN^10*, Brian J. Lannutti, PhD¹⁰, David M. Johnson, BS^10*, Langdon L. Miller, MD^10* and Stephen E. Spurgeon, MD¹³

¹Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
²Northwell Health System, New Hyde Park, NY
³Weill Cornell Medical College, New York, NY
⁴City of Hope, Duarte, CA
⁵Wilmot Cancer Institute, Medical Director, Clinical Trial Office, Professor of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
⁶University of California-San Diego, San Diego, CA
⁷University of California-Los Angeles, Los Angeles, CA
⁸University of Nebraska Medical Center, Omaha, NE
⁹Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
¹⁰VelosBio Inc., San Diego, CA
¹¹VelosBio Inc., Metuchen, NJ
¹²Ce3, Inc., Clinton, CT
¹³Oregon Health & Science University, Portland, OR

Mats Jerkeman, MD, PhD¹, Arne Kolstad, MD, PhD^2*, Carsten Utoft Niemann, MD, PhD³, Kirsten Groenbaek, MD, DMSc^4*, Martin Hutchings, MD, PhD^5*, Annika Pasanen, MD, PhD^6*, Sara Ekberg^7*, Karin Fahl Wader, MD, PhD^8* and Ingrid Glimelius, MD, PhD^9*

¹Department of Oncology, Lund University and Skane University Hospital, Lund, Sweden
²Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
³Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen O, Denmark
⁴The Epi-/Genome Laboratory, Department of Hematology/Rigshospitalet, Copenhagen, DNK
⁵Department of Hematology; Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark
⁶Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland
⁷Division of Clinical Epidemiology, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
⁸Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
⁹Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden